Lumos Pharma Says Growth Hormone Deficiency Trial Meet Expectations
Lumos Pharma Inc (NASDAQ:LUMO) announced interim results from its Phase 2 OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic (PK/PD) OraGrowtH212 Trial of…
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Oppenheimer Initiates Coverage On Lumos Pharma with Outperform Rating, Announces Price Target of $20
Oppenheimer analyst Leland Gershell initiates coverage on Lumos Pharma (NASDAQ:LUMO) with a Outperform rating and announces Price Target of $20.
Lumos Pharma: Q1 Earnings Insights
Lumos Pharma (NASDAQ:LUMO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Lumos Pharma missed estimated earnings by 3.37%, reporting an EPS of $-0.92 versus an estimate of $-0.89.
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Lumos Pharma’s Earnings: A Preview
Lumos Pharma (NASDAQ:LUMO) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement.
Analysts estimate that Lumos Pharma will report an earnings per share (EPS) of $-0.89.
Lumos Pharma Reaches 50% Randomization Milestone In Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 In PGHD
- Interim Data Anticipated by End of 2022 -
- Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 -
AUSTIN, Texas, April 11, 2022 (GLOBE NEWSWIRE)
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
Lumos Pharma European Patent Office Specification For Co.’s ‘DETECTING AND TREATING GROWTH HORMONE DEFICIENCY’
https://data.epo.org/publication-server/pdf-document?pn=3352752&ki=B1&cc=EP